What is Sutro Biopharma's AOCI?

Sutro Biopharma (STRO) reported AOCI of -$101K in Q1 2026.

How has Sutro Biopharma's AOCI changed year-over-year?

Sutro Biopharma's AOCI decreased by 1022.2% year-over-year, from -$9K to -$101K.

What is the long-term trend for Sutro Biopharma's AOCI?

Over 5 years (2020 to 2025), Sutro Biopharma's AOCI has grown at a -31.8% compound annual growth rate (CAGR), from $129K to $19K.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Sutro Biopharma STRO AOCI

AOCI at other companies

PfizerPFE

-$7.2B+16.1%

Gilead SciencesGILD

$78M-15.2%

RegenxbioRGNX

-$870K-14.2%

XencorXNCR

$27K-92.4%

AnaptysBio, Inc.ANAB

-$146K-191%

SchrodingerSDGR

-$28K-131%

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's AOCI?: Sutro Biopharma (STRO) reported AOCI of -$101K in Q1 2026.
How has Sutro Biopharma's AOCI changed year-over-year?: Sutro Biopharma's AOCI decreased by 1022.2% year-over-year, from -$9K to -$101K.
What is the long-term trend for Sutro Biopharma's AOCI?: Over 5 years (2020 to 2025), Sutro Biopharma's AOCI has grown at a -31.8% compound annual growth rate (CAGR), from $129K to $19K.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.